Podstawowe statystyki
| LEI | 549300UQE748N2H9LE74 |
| CIK | 1446159 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Axe Compute Inc.
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| May 18, 2026 |
Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update EXHIBIT 99.1 Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update Signed $260 Million Landmark Enterprise Contract - Largest in Company History Compute Services Revenue Commenced and Customer Prepayments Grew Appointed President and CFO to Executive Leadership Team PITTSBURGH, May 15, 2026 (GLOBE NEWSWIRE) - Axe Compute Inc. (NASDAQ: AGPU), a virtual neocloud |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Axe Compu |
|
| May 15, 2026 |
Up to $100,000,000 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024 and the Prospectus Supplements dated May 21, 2024, April 18, 2025, June 2, 2025, and October 29, 2025) Up to $100,000,000 Common Stock This prospectus supplement (this “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 12, 2026 |
EXHIBIT 99.1 Axe Compute to Host Q1 2026 Financial Results Conference Call Axe Compute Host Conference Call and Webcast on Monday, May 18, 2026 at 8:30 a.m. Eastern Time To Review First Quarter 2026 Financial Results PITTSBURGH, May 11, 2026 (GLOBE NEWSWIRE) - Axe Compute (NASDAQ: AGPU), a virtual neocloud AI infrastructure platform delivering dedicated enterprise GPU compute capacity at global sc |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 22, 2026 |
EXHIBIT 99.1 Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment Redefining enterprise AI infrastructure: enterprises no longer adapt to cloud constraints — they specify what they need, and Axe Compute delivers it PITTSBURGH, April 22, 2026 (GLOBE NEWSWIRE) - Axe Compute Inc. (NASDAQ: AGPU), a neocloud AI infrastructure platform delivering dedicate |
|
| April 16, 2026 |
AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE Exhibit 10.2 AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE Optionee: Jeremy Yaukey-Witter You have been awarded a non-qualified option to purchase shares of Common Stock of Axe Compute Inc., a Delaware corporation (the “Company”), as an inducement material to your acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”). The Induc |
|
| April 16, 2026 |
Exhibit 10.1 ***Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) made and entered into effective as of the 16th day of April, 2026 (the “Effective Date”) by and between Jeremy Yaukey-Witter, an individual, res |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 1, 2026 |
AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE EdgarFiling Exhibit 10.2 AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE Optionee: Kyle Okamoto You have been awarded a non-qualified option to purchase shares of Common Stock of Axe Compute Inc., a Delaware corporation (the “Company”), as an inducement material to your acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”). The I |
|
| April 1, 2026 |
EdgarFiling Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) made and entered into effective as of the 1st day of April, 2026 (the “Effective Date”) by and between Kyle Okamoto, an individual, residing at 6 China Lane, Setauket, NY 11733 (“Employee”) and Axe Compute Inc. headquartered at 91 43rd St., Suite 110, Pittsburgh, PA 15201, a Delaware corporation (“Company”), coll |
|
| April 1, 2026 |
EXHIBIT 99.1 Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026 $12M of Contract Value Across 20+ Enterprise Customers, Providing $835 Thousand in Estimated Monthly Income Starting Q2 2026 PITTSBURGH, April 01, 2026 (GLOBE NEWSWIRE) - Axe Compute Inc. (NASDAQ: AGPU), the newly transformed enterprise GPU infrastructure company |
|
| March 31, 2026 |
AXE COMPUTE INC. SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 AXE COMPUTE INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical Inc. Delaware |
|
| March 31, 2026 |
Axe Compute Inc. Reports Full-Year 2025 Financial Results EXHIBIT 99.1 Axe Compute Inc. Reports Full-Year 2025 Financial Results Completed Strategic Transformation to AI Compute Infrastructure Raised $343.5 Million in Capital to Fund Digital Asset Treasury Strategy Solidified new leadership composition with world class CEO and board members PITTSBURGH, March 31, 2026 (GLOBE NEWSWIRE) - Axe Compute Inc. (NASDAQ: AGPU), a technology company focused on prov |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Axe Compute Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36790 Axe Compute Inc. (Exact n |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 Axe Compute Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 9, 2026 |
Exhibit 10.1 AGREEMENT AND RELEASE This Agreement and Release (“Agreement”) is made by and between Raymond F. Vennare (“Employee”) and Axe Compute Inc. (formerly known as Predictive Oncology Inc.) (“the Company”), each of whom enter into this Agreement intending to be legally bound. 1. Background. The Company and Employee state the following facts and incorporate them by reference into this Agreem |
|
| February 9, 2026 |
AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE Exhibit 10.3 AXE COMPUTE INC. INDUCEMENT STOCK OPTION AWARD NOTICE Optionee: Christopher Miglino You have been awarded a non-qualified option to purchase shares of Common Stock of Axe Compute Inc., a Delaware corporation (the “Company”), as an inducement material to your acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”). The Induce |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026 Axe Compute Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 9, 2026 |
EXHIBIT 99.1 Axe Compute Appoints Christopher Miglino as Chief Executive Officer, Ushering in a New Era of Decentralized Compute PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) - Axe Compute (or the “Company”) (Nasdaq: AGPU) today announced the appointment of Christopher Miglino as Chief Executive Officer, marking a pivotal development in the company’s commitment to decentralized compute and digital in |
|
| February 9, 2026 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) made and entered into effective as of February 9, 2026 (the “Effective Date”) by and between Christopher Miglino (“Employee”), an individual, residing at 1688 Bahia Vista, Sarasota FL 34239, and Axe Compute Inc., 91 43rd St., Suite 110, Pittsburgh, PA 15201, a Delaware corporation (“Company”), collectively referred to as “th |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Axe Compute Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 12, 2025 |
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 ("Amendment") to the Employment Agreement dated November 1, 2022 (the “Employment Agreement”) is made and entered into effective as of December 10, 2025, by and between Raymond F. Vennare, an individual ("Employee"), and Predictive Oncology Inc., a Delaware corporation ("Company"). WHEREAS, the Board of Directors of the Comp |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 Axe Compute Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 12, 2025 |
(f/k/a Predictive Oncology Inc.) (Exact Name of Registrant as Specified in its Charter) Exhibit 107 Calculation of Filing Fee Tables S-8 Axe Compute Inc. (f/k/a Predictive Oncology Inc.) (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, pa |
|
| December 12, 2025 |
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure EXHIBIT 99.1 Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) - Axe Compute Inc. (NASDAQ: AGPU) (the “Company” or “Axe Compute”) today announced that it has changed its name to Axe Compute Inc., with its common stock to begin trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. Axe Compute will conti |
|
| December 12, 2025 |
As Filed with the Securities and Exchange Commission on December 12, 2025 As Filed with the Securities and Exchange Commission on December 12, 2025 Registration No. |
|
| December 11, 2025 |
Exhibit 3.2 THIRD Amended and Restated BYLAWS of AXE COMPUTE INC. Effective as of December 11, 2025 ARTICLE 1. OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaw |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2025 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 11, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF PREDICTIVE ONCOLOGY INC. (a Delaware corporation) Predictive Oncology Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. That the Board of Directors of the Corporation (the “Board”) has duly |
|
| December 2, 2025 |
Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement EXHIBIT 99.1 Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today announced that on December 1, 2025, |
|
| December 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 25, 2025 |
AMENDMENT NO. 1 TO THE PREDICTIVE ONCOLOGY INC. 2024 EQUITY INVENTIVE PLAN Exhibit 3.01 AMENDMENT NO. 1 TO THE PREDICTIVE ONCOLOGY INC. 2024 EQUITY INVENTIVE PLAN THIS AMENDMENT NO. 1 (the “Amendment”) to the Predictive Oncology Inc. 2024 Equity Incentive Plan (the “Plan”) is adopted as of October 14, 2025, subject to and effective upon the approval of the shareholders of Predictive Oncology Inc. (the “Company”) at the Company’s 2025 annual meeting of stockholders. W I T |
|
| November 25, 2025 |
Up to 14,903,393 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-291021 PROSPECTUS Up to 14,903,393 Shares of Common Stock This prospectus relates to the possible resale, from time to time by the selling stockholders named in this prospectus, of up to an aggregate of 14,903,393 shares (the “Shares”) of our common stock, par value $0.01 per share (“common stock”), underlying pre-funded warrants (the “Warrants |
|
| November 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 25, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organi |
|
| November 24, 2025 |
Up to 5,970,181 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-291022 PROSPECTUS Up to 5,970,181 Shares of Common Stock This prospectus relates to the possible resale, from time to time by the selling stockholders named in this prospectus, of up to an aggregate of 2,547,789 shares (the “PIPE Shares”) of our common stock, par value $0.01 per share (“common stock”), consisting of (i) 36,237 shares (the “Augu |
|
| November 21, 2025 |
November 21, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Lauren Nguyen, Office Chief Juan Grana, Staff Attorney Re: Predictive Oncology Inc. Registration Statement on Form S-3 Filed October 22, 2025 File No. 333-291021 Acceleration Request Requested Date: November 25, 2025 Requested Time: 4:00 P.M. Eastern Tim |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 20, 2025 |
November 20, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Lauren Nguyen, Office Chief Juan Grana, Staff Attorney Re: Predictive Oncology Inc. Registration Statement on Form S-3 Filed October 22, 2025 File No. 333-291022 Acceleration Request Requested Date: November 21, 2025 Requested Time: 4:00 P.M. Eastern Tim |
|
| November 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 Predictive Oncology Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carr |
|
| November 20, 2025 |
Registration No. 333-291022 As filed with the Securities and Exchange Commission on November 20, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organi |
|
| November 17, 2025 |
Exhibit 99.1 1 This presentation contains “forward - looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This presentation also includes express and implied forward - looking statements regarding the Company’s current expectations, estimates, opinions and belief |
|
| November 14, 2025 |
EXHIBIT 99.1 Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy Company to host investor conference call and webcast on Monday, November 17th, at 9:00am EST PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy |
|
| November 14, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 26, 2025, between Predictive Oncology Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature page hereto (including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predi |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 29, 2025 |
Up to $18,330,000 Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024 and the Prospectus Supplements dated May 21, 2024, April 18, 2025, and June 2, 2025) Up to $18,330,000 Common Stock This prospectus supplement (this “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed with the Securitie |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 29, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organiz |
|
| October 28, 2025 |
81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'& )250. |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| October 22, 2025 |
Registration No. 333- As filed with the Securities and Exchange Commission on October 22, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organiza |
|
| October 22, 2025 |
Calculation of Filing Fee Tables S-3 Predictive Oncology Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| October 22, 2025 |
Registration No. 333- As filed with the Securities and Exchange Commission on October 22, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organiza |
|
| October 22, 2025 |
Calculation of Filing Fee Tables S-3 Predictive Oncology Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| October 8, 2025 |
EXHIBIT 99.1 Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy Investment creates the world’s first Strategic Compute Reserve Strategy complements Predictive Oncology’s AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (“Predictive Oncology” or the |
|
| October 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 30, 2025 |
Exhibit 10.6 STRATEGIC ADVISOR AGREEMENT This Strategic Advisor Agreement (the “Agreement”) is entered into as of October , 2025 (the “Effective Date”), by and between Predictive Oncology, Inc., a Delaware corporation with its principal place of business at 91 43rd Street, Suite 110, Pittsburgh, Pennsylvania 15201 (“Company”), and DNA Holdings Venture, Inc., a Puerto Rico corporation with its prin |
|
| September 30, 2025 |
Exhibit 99.2 AETHIR DIGITAL ASSET TREASURY: POWERING THE AI INFRASTRUCTURE REVOLUTION Infrastructure - Backed Yield via the World’s Largest Decentralized GPU Network and $ATH Token CONFIDENTIAL DNA HOLDINGS VENTURES, INC This presentation is being delivered to a limited number of parties for discussion purposes only and shall not form the basis for or be relied on in connection with any contractua |
|
| September 30, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [●], 2025, between Predictive Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co |
|
| September 30, 2025 |
Exhibit 10.5 September 29, 2025 PREDICTIVE ONCOLOGY 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 Re: Predictive Oncology ATH Digital Asset Treasury Transaction Ladies and Gentlemen: Reference is made to the Securities Purchase Agreement, dated as of September 29, 2025 (the “SPA”), by and among Predictive Oncology Inc., a Delaware corporation (the “Company”) and the purchasers set forth |
|
| September 30, 2025 |
COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY, Inc. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 30, 2025 |
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY, Inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 30, 2025 |
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 30, 2025 |
Risks Related to the Company’s Business and Aethir Strategy and Holdings Exhibit 99.3 Risks Related to the Company’s Business and Aethir Strategy and Holdings We intend to use the net proceeds from the Private Placements (as defined in our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on September 29, 2025) principally to purchase digital assets, including Aethir tokens, the price of which has been, and will likely continue to be, h |
|
| September 30, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September [●], 2025, between Predictive Oncology, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organ |
|
| September 30, 2025 |
AMENDMENT NO. 2 TO THE SECOND AMENDED AND RESTATED BYLAWS OF PREDICTIVE ONCOLOGY INC. Exhibit 3.1 AMENDMENT NO. 2 TO THE SECOND AMENDED AND RESTATED BYLAWS OF PREDICTIVE ONCOLOGY INC. The Second Amended and Restated Bylaws, as amended on September 9, 2022 (the “Bylaws”) of Predictive Oncology Inc., a Delaware corporation (the “Company”) are hereby amended pursuant to Section 6.06 of the Bylaws as follows: 1. Section 3.02 of the Bylaws is hereby deleted in its entirety and replaced |
|
| September 30, 2025 |
Exhibit 10.7 ASSET MANAGEMENT AGREEMENT This ASSET MANAGEMENT AGREEMENT (this “Agreement”), effective October [], 2025 (the “Effective Date”), is entered into by and between Predictive Oncology Inc. (the “Client”), and DNA Holdings Venture, Inc. (the “Asset Manager” and, together with the Client, the “Parties”). WHEREAS, the Client wishes to appoint the Asset Manager to manage certain assets of th |
|
| September 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [●], 2025, between Predictive Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co |
|
| September 30, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 30, 2025 |
Exhibit 10.4 LOCK-UP AGREEMENT , 2025 Predictive Oncology Inc. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 Re: (i) Securities Purchase Agreement, dated as of , 2025 (the “Cash Purchase Agreement”), between Predictive Oncology Inc. (the “Company”) and the purchasers signatory thereto (each, a “Cash Purchaser” and, collectively, the “Cash Purchasers”), and (ii) Securities Purchase Agreement, date |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 29, 2025 |
EXHIBIT 99.1 Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its artificial intelligence and machine learnin |
|
| September 25, 2025 |
Exhibit 99.1 Predictive Oncology Announces 1-for-15 Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025 PITTSBURGH, PA. – September 25, 2025 – Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common st |
|
| September 25, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF PREDICTIVE ONCOLOGY INC. (a Delaware corporation) Pursuant to Section 242 of the Delaware General Corporation Law, the undersigned, being the Chief Executive Officer of Predictive Oncology Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that the fo |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 19, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organ |
|
| September 12, 2025 |
PREDICTIVE ONCOLOGY INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.1 PREDICTIVE ONCOLOGY INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Name of Grantee: [●] No. of Restricted Stock Units: [●] Grant Date: [●] Pursuant to the Predictive Oncology Inc. 2024 Equity Incentive Plan, as amended from time to time (the “Plan”), Predictive Oncology Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed ab |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organi |
|
| September 8, 2025 |
X0708 D LIVE 0001446159 Predictive Oncology Inc. 91 43RD STREET SUITE 110 PITTSBURGH PA PENNSYLVANIA 15201 412-432-1500 DELAWARE Precision Therapeutics Inc. Precision Therapeutic Inc. Skyline Medical Inc. Corporation true Raymond F. Bennare 91 43rd Street Suite 110 Pittsburgh PA PENNSYLVANIA 15201 Executive Officer Director Veena Rao 91 43rd Street Suite 110 Pittsburgh PA PENNSYLVANIA 15201 Direct |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organiza |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| August 14, 2025 |
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discover |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| July 29, 2025 |
Up to 1,921,706 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-288782 PROSPECTUS Up to 1,921,706 Shares of Common Stock This prospectus relates to the resale from time to time by YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville” or the “Selling Stockholder”) of up to 1,921,706 shares of our Common Stock, par value $0.01 per share (“Common Stock”). The shares of Common Stock to which this |
|
| July 24, 2025 |
July 24, 2025 Josh Blacher Interim Chief Financial Officer Predictive Oncology Inc. |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| July 24, 2025 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 July 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-288782 Requested Date: July 28, 2025 Requested Time |
|
| July 18, 2025 |
Exhibit 99.1 EXPLANATORY NOTE Predictive Oncology is revising and recasting certain financial and other information included in its 2024 Form 10-K. The relevant information in the 2024 Form 10-K is being updated to retrospectively reflect the results of the Eagan Business as discontinued operations as a result of meeting the criteria for discontinued operations during the three months ended March |
|
| July 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Predictive Oncology Inc. |
|
| July 18, 2025 |
As Filed with the Securities and Exchange Commission on July 18, 2025 As Filed with the Securities and Exchange Commission on July 18, 2025 Registration No. |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| July 11, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizatio |
|
| July 8, 2025 |
Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 1, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and PREDICTIVE ONCOLOGY INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individu |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizatio |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 2, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated April 18, 2025 (To Prospectus and Prospectus Supplement dated May 21, 2024) Up to $3,398,000 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated April 18, 2025, to the prospectus, dated |
|
| May 15, 2025 |
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictiv |
|
| April 18, 2025 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-279123 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement dated May 21, 2024) Up to $1,491,000 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of our registration statem |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organiza |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organizati |
|
| April 1, 2025 |
Predictive Oncology Inc. 2024 Equity Incentive Plan Exhibit 99.1 PREDICTIVE ONCOLOGY INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the 2024 Equity Incentive Plan (the “Plan”) of Predictive Oncology Inc. (the “Company”) is to increase shareholder value and to advance the interests of the Company by furnishing a variety of economic incentives (“Incentives”) designed to attract, retain and motivate employees, certain key consultants and d |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Predictive Oncology Inc. |
|
| April 1, 2025 |
As Filed with the Securities and Exchange Commission on March 31, 2025 As Filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| April 1, 2025 |
EXHIBIT 99.1 Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update Company continues to progress toward the signing of a definitive merger agreement with Renovaro PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensiv |
|
| March 31, 2025 |
Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 31, 2025 |
Exhibit 19 PREDICTIVE ONCOLOGY INC. POLICY ON AVOIDANCE OF INSIDER TRADING The Board of Directors of Predictive Oncology Inc., a Delaware corporation (the “Company”), has adopted this Insider Trading Policy for our directors, employees (including officers) and consultants with respect to the trading of the Company’s securities, as well as the securities of publicly traded companies with whom we ha |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36790 Predictive Oncology Inc. |
|
| March 31, 2025 |
Exhibit 4.7 Description of Registrant’s Securities Predictive Oncology Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), namely, our common stock, par value $0.01 per share (“Common Stock”). Description of Common Stock The following description of our Common Stock is a summary and does not purport t |
|
| March 20, 2025 |
EXHIBIT 99.1 Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences PITTSBURGH, March 20, 2025 (GLOBE NEWSWIRE) - |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 20, 2025 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) dated as of March 14, 2025 is entered into between Predictive Oncology Inc., a Delaware corporation (“Seller”), and DeRoyal Industries, Inc., a Tennessee corporation (“Buyer”). Capitalized terms used in this Agreement have the meanings given to such terms herein. RECITALS WHEREAS, in addition to its other busine |
|
| March 5, 2025 |
EXHIBIT 99.1 Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro’s recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology’s bioma |
|
| March 5, 2025 |
Exhibit 10.1 EXTENSION AGREEMENT This Extension Agreement (“Agreement”) is entered into this 28th day of February 2025, by Predictive Oncology, Inc., a Delaware corporation (the “POI”), and Renovaro, Inc. a Delaware corporation (the, “Renovaro”)(collectively, POI and Renovaro may be referred to as the “Parties”). BACKGROUND WHEREAS, POI and Renovaro entered into a definitive Letter agreement dated |
|
| March 5, 2025 |
Exhibit 10.1 EXTENSION AGREEMENT This Extension Agreement (“Agreement”) is entered into this 28th day of February 2025, by Predictive Oncology, Inc., a Delaware corporation (the “POI”), and Renovaro, Inc. a Delaware corporation (the, “Renovaro”)(collectively, POI and Renovaro may be referred to as the “Parties”). BACKGROUND WHEREAS, POI and Renovaro entered into a definitive Letter agreement dated |
|
| March 5, 2025 |
EXHIBIT 99.1 Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro’s recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology’s bioma |
|
| March 5, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 5, 2025 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) |
|
| February 19, 2025 |
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.1 Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced that it has entered into definitive agreements for the purchase and sale of 363,336 shares of c |
|
| February 19, 2025 |
PREDICTIVE ONCOLOGY INC. 363,336 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) File No. 333-279123 PREDICTIVE ONCOLOGY INC. 363,336 Shares of Common Stock We are offering 363,336 shares of our common stock, par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus, directly to institutional investors. Our common stock is listed on The Nasdaq Capital Market under the symbol “POAI.” |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 19, 2025 |
Form of Securities Purchase Agreement dated February 18, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 18, 2025, between Predictive Oncology Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| February 19, 2025 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 19, 2025 |
Predictive Oncology Closes Registered Direct Offering EXHIBIT 99.2 Predictive Oncology Closes Registered Direct Offering PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 |
|
| January 13, 2025 |
1,983,302 Shares of Common Stock Issuable Upon Exercise of Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333- 281579 PROSPECTUS 1,983,302 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 1,983,302 shares of our common stock, par value $0.01 per share. These shares consist of (i) 958,117 shares of comm |
|
| January 6, 2025 |
Letter of Intent between Predictive Oncology and Renovaro Exhibit 1.01 January 1, 2025 Raymond Vennare Predictive Oncology Inc. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 Confidential Dear Raymond, Thank you very much for the opportunity to review Predictive Oncology Inc. (referred to as the “Company”, “Predictive”, or the “Seller”). We have enjoyed our discussions with you to date and are excited about your business model and prospects and very enco |
|
| January 6, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 6, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 6, 2025 |
EXHIBIT 99.1 Predictive Oncology Announces Agreement to be Acquired by Renovaro - Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders’ interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GL |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabil |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predi |
|
| September 20, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organ |
|
| August 21, 2024 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 August 21, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park, Staff Attorney Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-3, as amended File No. 333-281579 Requested Date: A |
|
| August 21, 2024 |
August 21, 2024 Raymond Vennare Chief Executive Officer Predictive Oncology Inc. 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 Re: Predictive Oncology Inc. Registration Statement on Form S-3 Filed August 15, 2024 File No. 333-281579 Dear Raymond Vennare: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 reg |
|
| August 15, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on August 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organizat |
|
| August 15, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 14, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update Company to host investor call and webcast today, August 14th, at 8:30am EDT PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive |
|
| July 29, 2024 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 29, 2024 |
EdgarFiling EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF |
|
| July 29, 2024 |
Form of Placement Agent Warrant EdgarFiling EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFF |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 29, 2024 |
Form of Warrant Inducement Agreement EdgarFiling EXHIBIT 4.4 Predictive Oncology Inc. July 25, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Predictive Oncology Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.000 |
|
| July 29, 2024 |
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds EXHIBIT 99.1 Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its commo |
|
| May 30, 2024 |
EXHIBIT 99.1 Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Study successfully demonstrated Predictive’s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone PIT |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 21, 2024 |
Registration No. 333-279123 As filed with the Securities and Exchange Commission on May 21, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of inco |
|
| May 21, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| May 20, 2024 |
PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 PREDICTIVE ONCOLOGY INC. 91 43rd Street, Suite 110 Pittsburgh, PA 15201 May 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park, Staff Attorney Re: Predictive Oncology Inc. Acceleration Request for Registration Statement on Form S-3, as amended File No. 333-279123 Requested Date: May |
|
| May 15, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 8:30am EDT PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tu |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictiv |
|
| May 13, 2024 |
United States securities and exchange commission logo May 13, 2024 Raymond Vennare Chief Executive Officer Predictive Oncology Inc. |
|
| May 6, 2024 |
Exhibit 1.2 Execution Version PREDICTIVE ONCOLOGY INC. Common Stock (par value $0.01 per share) ATM Sales Agreement May 3, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Predictive Oncology Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) as follows: 1. Issuance |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or other jurisdiction of incorporation or organization |
|
| May 6, 2024 |
Exhibit 4.43 Predictive Oncology, Inc. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establishment |
|
| May 6, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Predictive Oncology Inc. |
|
| May 6, 2024 |
Exhibit 10.1 Execution Version PREDICTIVE ONCOLOGY INC. Common Stock (par value $0.01 per share) ATM Sales Agreement May 3, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Predictive Oncology Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) as follows: 1. Issuanc |
|
| May 6, 2024 |
Registration No. 333- As filed with the Securities and Exchange Commission on May 3, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or jurisdiction (I.R.S. Employer of incorporation or organization) |
|
| April 8, 2024 |
Letter of BDO USA, P.C. to the Securities and Exchange Commission, dated April 8, 2024. Exhibit 16.1 Tel: 612-367-3000 Fax: 612-367-3001 www.bdo.com 800 Nicollet Mall, Suite 600 Minneapolis, MN 55402 April 8, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 3, 2024, to be filed by our former client, Predictive Oncology Inc. We agree with the |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 28, 2024 |
EXHIBIT 99.1 Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of |
|
| March 28, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97 PREDICTIVE ONCOLOGY INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Purpose The purpose of this policy is to set forth the procedures established by the Predictive Oncology (the “Company”) Board of Directors (the “Board”) for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with the financial reporting r |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36790 Predictive Oncology Inc. |
|
| March 28, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 28, 2024 |
Exhibit 10.9 SEPARATION AGREEMENT AND MUTUAL RELEASE This Separation Agreement and Mutual Release ("Agreement") is made by and between Robert Myers ("Employee") and Predictive Oncology Inc. (the "Company"), each of whom enter into this Agreement intending to be legally bound. 1. Terms of Employment; Separation Date. a. The terms of Employee's employment with the Company are set forth in that certa |
|
| March 22, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 14, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, November 14th, at 8:30am EDT PITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc. |
|
| August 10, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 10, 2023 Predictive Oncology Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology Inc |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2023 |
EXHIBIT 99.1 Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 2, 2023 |
EXHIBIT 99.1 Predictive Oncology Appoints Pharma, Biotech and Digital Health Veteran Veena Rao, PhD, MBA, to its Board of Directors EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvem |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 20, 2023 |
EXHIBIT 99.1 Predictive Oncology Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-spli |
|
| April 20, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF PREDICTIVE ONCOLOGY INC. (a Delaware corporation) Pursuant to Section 242 of the Delaware General Corporation Law, the undersigned, being the Chief Financial Officer of Predictive Oncology Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that the fo |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 5, 2023 |
Exhibit 16.1 Baker Tilly US, LLP 225 S Sixth St, Ste 2300 Minneapolis, MN 55402-4661 T: +1 (612) 876 4500 F: +1 (612) 238 8900 bakertilly.com April 4, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K, dated on or about April 4, 2023, of Predictive Oncology Inc. and agree with the statements contained in the sec |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 21, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 PREDICTIVE ONCOLOGY INC. SUBSIDIARIES OF THE REGISTRANT Subsidiary Jurisdiction of Incorporation Helomics Corporation Delaware Skyline Medical, Inc. Delaware |
|
| March 21, 2023 |
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EXHIBIT 99.1 Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) labora |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022. |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 33-1007393 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| March 16, 2023 |
EXHIBIT 99.1 Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0 |
|
| March 16, 2023 |
Exhibit 3.1 PREDICTIVE ONCOLOGY INC. CERTIFICATE OF DESIGNATION OF SERIES F PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Predictive Oncology Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with the p |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 14, 2023 |
EXHIBIT 99.1 Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) - Predictive Oncology (Nasdaq: POAI) |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2023 |
Employment Agreement dated February 23, 2023 by and between Pamela Bush and Predictive Oncology Inc. Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) made and entered into on February 23, 2023, to be effective as of February 1, 2023 (the “Effective Date”) by and between Pamela Bush, an individual, residing at 13418 Canopy Creek Drive, Tampa, Florida 33625 (“Employee”), and Predictive Oncology Inc., 2915 Commers Drive, Suite 900, E |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Inco |
|
| February 3, 2023 |
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer Exhibit 99.1 Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 5, 2022 |
EXHIBIT 99.1 Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company?s strategic initiatives and commercia |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36790 Predictive Oncology |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2022 |
Predictive Oncology Reports Third Quarter Financial Results Exhibit 99.1 Predictive Oncology Reports Third Quarter Financial Results EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) - Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods. Highlights from the quarter include: Raymond |
|
| October 25, 2022 |
Exhibit 99.1 David S. Smith appointed to the Board of Directors of Predictive Oncology Leading authority on the therapeutic use of human tissues and cells EAGAN, Minn., Oct. 25, 2022 (GLOBE NEWSWIRE) – Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors. Mr. Smith is a life sciences and corporate attorney, veteran bio |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 20, 2022 |
EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 September 30, 2022 Raymond Vennare 179 West Hutchinson Avenue Pittsburgh, PA 1528-1321 Dear Raymond: On behalf of Predictive Oncology Inc. (the “Company”), I am very pleased to offer you the position of Chief Executive Officer of Predictive Oncology Inc. This letter establishes the terms of your employment with the Company if you accept this offer. Yo |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 22, 2022 Predictive Oncology Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id |
|
| October 20, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) made and entered into effective as of the 1st day of November 2022 (the ?Effective Date?) by and between Raymond F. Vennare, an individual, residing at 179 West Hutchinson Avenue, Pittsburgh, PA 15218, and Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, Minnesota 55121, a Delaware corporation (?Company?), col |
|
| October 20, 2022 |
Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth EXHIBIT 99.1 Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth EAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1. As an active member on the POAI Board of Directors since September 2021 |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 13, 2022 |
PREDICTIVE ONCOLOGY INC. 4,737,280 Shares Common Stock Filed pursuant to 424(b)(3) Registration No. 333-267689 PROSPECTUS PREDICTIVE ONCOLOGY INC. 4,737,280 Shares Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 4,737,280 shares of our common stock, par value $0.01 per share. These shares consist of (i) 3,837,280 shares of common stock issuable |
|
| October 11, 2022 |
Predictive Oncology, Inc. 2915 Commers Drive, Suite 900 Eagan, MN 55121 CORRESP 1 filename1.htm Predictive Oncology, Inc. 2915 Commers Drive, Suite 900 Eagan, MN 55121 October 11, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Benjamin Richie Re: Predictive Oncology, Inc. Registration Statement on Form S-1 File No. 333-267689 Ladies and Gentlemen: Pursuant to Rule 461 u |
|
| October 6, 2022 |
United States securities and exchange commission logo October 6, 2022 Bob Myers Chief Financial Officer Predictive Oncology Inc. |
|
| September 30, 2022 |
Exhibit 3.10 SECOND Amended and Restated BYLAWS of PREDICTIVE ONCOLOGY INC. Effective as of September 9, 2022 ARTICLE 1. OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the Stat |
|
| September 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Predictive Oncology Inc. |
|
| September 30, 2022 |
S-1 1 fs1093022.htm FORM S-1 Registration No. 333- As filed with the Securities and Exchange Commission on September 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 3842 33-1007393 (State or jurisdiction (Primary |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaware 001-36790 33-1007393 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 16, 2022 |
Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (?Agreement?) is made and entered into effective as of September 15, 2022, by and between J. Melville Engle (?Employee?) and Predictive Oncology Inc., a Delaware corporation (?the Company?), each of whom enter into this Agreement intending to be legally bound. RECITALS The Company and Employee agree upon the |
|
| September 16, 2022 |
Predictive Oncology Announces CEO Retirement EXHIBIT 99.1 Predictive Oncology Announces CEO Retirement EAGAN, Minn., Sept. 16, 2022 (GLOBE NEWSWIRE) - Predictive Oncology (NASDAQ: POAI) today announced that J. Melville (?Mel?) Engle will retire as Chief Executive Officer and as Chairman and a member of the company?s Board of Directors. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through |
